NCT05237349 2024-01-05
Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
Clinical Trials
10 trialsNCT06170697 2023-12-20
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05460195 2022-07-15
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation
Shanghai Chest Hospital
Phase 2 Unknown
NCT05422183 2022-06-16
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Zhongda Hospital
Phase 2 Unknown
NCT04174781 2022-06-09
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
Zhejiang University
Phase 2 Unknown
NCT05298020 2022-03-28
Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer
The Affiliated Hospital of Xuzhou Medical University
Phase 2 Unknown
NCT05240404 2022-02-15
Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
Xiangya Hospital of Central South University
Phase 2 Unknown
NCT04981665 2022-01-05
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
Zhejiang University
Phase 2 Unknown
NCT04333927 2020-06-23
ACCORD
Sun Yat-sen University
Phase 2 Unknown
NCT04413734 2020-06-04
Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma
Zhejiang University
Phase 2 Unknown